December 26, 2019
Triplet Regimen Offers Improved Outcomes in BRAF-Mutant Colorectal Cancer BookmarkGeorge Lundberg, MD
Article from Cancer Network curated by Editor in Chief George Lundberg, MD, who notes:
In a phase III clinical trial, a triple-drug therapy nearly triples overall survival for patients with colorectal cancer.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.